The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody via Continuation or Rechallenge After the Occurrence of Immune-Related Adverse Events

Overview of attention for article published in Frontiers in oncology, September 2021

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 14 Dimensions

Readers on

mendeley: 7 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 14 publications that cite this research output.

14

The most recent citing publications are shown below. View all 14 publications that cite this research output on Dimensions.

Safety, efficacy, and survival outcomes of immune checkpoint inhibitors rechallenge in patients with cancer: a systematic review and meta-analysis

Article in The Oncologist (June 2024)

Safety and efficacy of restarting immune checkpoint inhibitors in non-small cell lung cancer patients following immune-related adverse events: a systematic review and meta-analysis

Article in Clinical and Translational Oncology (June 2024)

Anti‐PD‐L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy‐refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study

Article in Cancer (May 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.